Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.20 per share a year ago.

Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates

FY 2023 Revenue Increased 17% to $184.3 Million Company Announces Additional $20 Million Stock Repurchase Plan ENGLEWOOD, Colo. , Feb. 29, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2023 and its Board of Directors has approved an additional program to repurchase up to $20.0 million of the Company's common stock.

Zynex Reports Fourth Quarter and Full Year 2023 Financial Results

ENGLEWOOD, Colo. , Feb. 22, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023.

Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call

ENGLEWOOD, Colo. , Feb. 20, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, introduced two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression.

Zynex Introduces New Products

ENGLEWOOD, Colo. , Feb. 6, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.

Zynex Receives FDA Clearance for its Next Generation NMES Device

ENGLEWOOD, Colo. , Feb. 2, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024.

Zynex Recognized in Top 25 Medical Device Companies for 2024

Gambling.com Group

Spire Global

The stock market recovery over the past couple of years has been anything but evenly-distributed. A handful of high-flying tech stocks dubbed the “Magnificent Seven” have largely powered the rebound, overshadowing many other quality businesses.

3 Unloved Growth Stocks Poised for a Major Turnaround

ENGLEWOOD, Colo. , Jan. 8, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will participate virtually in the upcoming Needham Annual Growth Conference, which is being held January 16 th-19th, 2024.

Zynex to Participate at the Needham Annual Growth Conference

ENGLEWOOD, Colo. , Nov. 15, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company has been ranked within Forbes' list of America's Most Successful Small-Cap Companies for 2024.

Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024"

ENGLEWOOD, Colo. , Nov. 13, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for the M-Wave Neuromuscular Electrical Stimulation ("NMES") device.

Zynex Submits FDA Application for its Next Generation NMES Device

ENGLEWOOD, Colo. , Nov. 9, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company has been ranked among all companies in the U.S. and Canada between 2019 and 2022 on Deloitte's Technology Fast 500.

Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year

ENGLEWOOD, Colo. , Nov. 1, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to repurchase up to $20.0 million of the Company's common stock.

Zynex Announces Share Repurchase Program

ENGLEWOOD, Colo. , Oct. 31, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its Board of Directors (the "Board") has initiated a process to evaluate potential strategic alternatives to maximize shareholder value.

Zynex Announces Review of Strategic Alternatives

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.13 per share a year ago.

Zynex Inc. (ZYXI) Q3 Earnings Match Estimates

Zynex, Inc. (NASDAQ:ZYXI ) Q3 2023 Earnings Conference Call October 26, 2023 4:15 PM ET Company Participants Quinn Callanan - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Daniel Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Shagun Singh Chadha - RBC Yi Chen - H.C. Wainwright Operator Good day ladies and gentlemen, and welcome to the Zynex Third Quarter 2023 Earnings Conference Call.

Zynex, Inc. (ZYXI) Q3 2023 Earnings Call Transcript

Q3 2023 Revenue Increased 20% to $49.9 Million; EPS $0.10 ENGLEWOOD, Colo. , Oct. 26, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial and operational results for the third quarter ended September 30, 2023.

Zynex Reports Third Quarter 2023 Financial Results

ENGLEWOOD, Colo. , Oct. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex as 23rd in the Top 100 Healthcare Technology Companies of 2023.

Zynex Recognized in Top 100 Healthcare Technologies Companies for Second Year in a Row

ENGLEWOOD, Colo. , Oct. 12, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 26, 2023 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2023.

Zynex, Inc Sets Third Quarter 2023 Earnings Call

FARO Technologies

Gevo

The Federal Reserve signaling interest rates could stay elevated for the long term coupled with relentless political infighting in Washington has brought another jolt of volatility to equities. This has led to this list of micro-cap stocks to sell.

3 Micro-Cap Stocks to Sell While You Still Can

Zynex, Inc. is a pain management company that manufactures and markets medical devices for chronic and acute pain treatment. The stock has fallen by half since we took a first look at it in April despite being profitable and having better than 20% revenue growth. Is Zynex now in the 'buy zone?" An updated analysis follows in the paragraphs below.

Zynex: A Reassessment

ENGLEWOOD, Colo. , Sept. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming Cantor Global Healthcare Conference, which is being held September 26 th-28th, 2023.

Zynex to Present at the Cantor Global Healthcare Conference

ENGLEWOOD, Colo., Sept. 5, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming H.C.

Zynex to Present at the H.C. Wainwright Global Investment Conference

ENGLEWOOD, Colo. , Aug. 10, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that, since its founding, the company has treated more than 1 million patients through its pain management division.

Zynex Announces 1 Millionth Patient Milestone

ENGLEWOOD, Colo. , Aug. 9, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management.

Zynex, Inc Announces New Therapy Products

ENGLEWOOD, Colo. , Aug. 3, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has the company's Founder and CEO, Thomas Sandgaard will participate in Benzinga's Pharma Companies vs.

Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET

News for Zynex Inc Stock (ZYXI)